ストックスクリーナーアプリを入手
135.87
0.07%
0.10
アフターアワーズ：
136.81
0.94
+0.69%
前日終値:
$135.77
開ける：
$133.99
24時間の取引高:
5.68M
Relative Volume:
0.76
時価総額：
$168.47B
収益：
$29.79B
当期純損益:
$9.22B
株価収益率:
18.49
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
+3.12%
1か月 パフォーマンス:
+4.65%
6か月 パフォーマンス:
-10.50%
1年 パフォーマンス:
+13.21%
1日の値動き範囲:
$133.29
$137.12
1週間の範囲:
$129.02
$137.12
52週間の値動き範囲:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
135.87 | 168.35B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,220.28 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.86 | 626.09B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
248.76 | 441.94B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
132.92 | 321.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.32 | 293.87B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics - finance.yahoo.com
FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst - MarketBeat
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Benzinga
MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com South Africa
MacroGenics stock rises on $10M Gilead option exercise - Investing.com
Gilead Sciences (GILD) EVP converts 6,002 RSUs, with 2,908 shares withheld - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - The Manila Times
Gilead Sciences options activity points to institutional conviction on 2026 upside - Investing.com
Gilead Sciences Target of Unusually High Options Trading (NASDAQ:GILD) - MarketBeat
FY2027 EPS Estimate for Gilead Sciences Lowered by Analyst - MarketBeat
Handelsbanken Fonder AB Has $123.19 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
E. Ohman J or Asset Management AB Has $5.66 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call - The Globe and Mail
Why Gilead Sciences (NASDAQ:GILD) Just Won a Key Drug Development Case? - kalkinemedia.com
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade) - Seeking Alpha
Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring a Potential 18.16% Upside with Robust Pipeline and Strategic Collaborations - DirectorsTalk Interviews
Gilead Sciences, Inc. Revenue Breakdown – SIX:GILD - TradingView
Ebola response turns to Merck vaccine, Gilead drug as Congo outbreak worsens - The Spokesman-Review
AB RELATIVE VALUE FUND, INC.'s Gilead Sciences Inc(GILD) Holding History - GuruFocus
Should Gilead’s Swing to a Full‑Year Loss Outlook Require Action From Gilead Sciences (GILD) Investors? - webull.com
Key HIV stat over 70% leaves BofA siding with Gilead - thestreet.com
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results - The National Law Review
Ebola Response Turns to Merck Vaccine, Gilead Drug as Congo Outbreak Worsens - Bloomberg.com
Czech National Bank Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
PensionDanmark Pensionsforsikringsaktieselskab Purchases 25,515 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
NewEdge Advisors LLC Buys 231,715 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Assenagon Asset Management S.A. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ: GILD) sets up automatic shelf for wide range of securities - Stock Titan
GILEAD SCIENCES, INC. 2026: Revenue $7.8B, EPS ($8.45) — 10-Q Summary - TradingView
Gilead Sciences: A Strong Quarter Hidden Behind A Bottom-Line Loss (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says - Moomoo
Gilead Sciences (NASDAQ:GILD) Given New $123.00 Price Target at Royal Bank Of Canada - MarketBeat
Gilead Sciences Inc Stock (GILD) Moved Down by 3.96% on Aug 5: A Full Analysis - TradingKey
Gilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare Foundation - finance.yahoo.com
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch - BioPharma Dive
Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126 - Moomoo
Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130 - finance.yahoo.com
Gilead Sciences, Inc. Declares Quarterly Dividend of $0.82 (NASDAQ:GILD) - MarketBeat
The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth - finance.yahoo.com
Gilead Sciences (GILD) Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation - Sahm
Gilead's Steady Long-Term Growth Prospects in HIV and Expansion in Oncology Support a Wide Moat - Morningstar
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ... - Yahoo Finance
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: P - GuruFocus
Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock - MarketBeat
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results - Business Wire
Gilead Sciences (GILD) Chairman & CEO Daniel O'Day Sells 15,000 Shares - GuruFocus
Gilead Sciences Q2 Earnings Call Highlights - MarketBeat
Is Gilead Sciences Inc (GILD) Worth the Current Valuation? Q2 Ea - GuruFocus
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
1.16%
0.45%
大文字化:
|
ボリューム (24 時間):